• Business Combination Facilitation: This service involves identifying and executing mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or other business combinations with one or more target businesses.

Instinct Bio Technical Company (BIOT) is described as a Biotech Acquisition Company that "does not have significant operations" and intends to "effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses."

Based on this description, BIOT is a Special Purpose Acquisition Company (SPAC). SPACs are formed to raise capital through an initial public offering (IPO) with the sole purpose of acquiring an existing private company, thereby taking it public. As such, SPACs do not have traditional customers who purchase products or services.

Therefore, Instinct Bio Technical Company (BIOT) does not have major customers or categories of customers to report at this stage of its operations.

Tomoki Nagano, Chairman & CEO

Born in 1981 in Yamaguchi Prefecture, Tomoki Nagano began his career in the cosmetics industry. He founded HIROKI GLOBAL Inc. in 2017, and later became the Representative Director of INSTINCT BROTHERS Inc. in 2021, advancing to Chairman & CEO of the same company from 2022. As the founder of Instinct Brothers Co. Ltd., he is recognized as a visionary leader with extensive experience in business management and entrepreneurship. He leads the group's business with the motto of "Bringing joy to people around the world and spreading more smiles."

Masashi Ohmatsu, Chief Financial Officer

Masashi Ohmatsu holds a degree in Economics from Okayama University and brings over 30 years of experience in the financial services industry.

Yuji Naito, Director & COO

Born in 1979 in Shizuoka Prefecture, Yuji Naito's career includes work in agriculture and food-related businesses, as well as assisting over 30 brands with their international expansion. He was appointed Senior Managing Director of INSTINCT BROTHERS Inc. in 2021.

Fumihiro Nagano, Director & CMO

Born in 1978 in Yamaguchi Prefecture, Fumihiro Nagano served as a sports trainer, including as a medical science staff member for the Japan Olympic Committee. After managing several facilities, he became the Representative Director and President of INSTINCT BROTHERS Inc. in 2023.

Futa Sakakibara, Ph.D., Chief Technology Officer

Futa Sakakibara holds a Ph.D. in Agricultural Chemistry from Tokyo University of Agriculture Graduate School. He possesses specialized qualifications in aviation and travel medicine and is involved in medical collaborations in Southeast Asia.

The key risk to Instinct Bio Technical Company (BIOT) is the following:

1. Failure to Complete a Business Combination: As a company that currently has no significant operations and whose primary purpose is to effect a merger, share exchange, asset acquisition, or other business combination, the dominant risk is its inability to successfully identify and complete such a transaction within its specified timeframe. If Instinct Bio Technical Company fails to complete a business combination, it would likely be forced to liquidate, and investors would receive a pro-rata share of the funds held in its trust account, thereby losing the opportunity for any potential upside from a successful operational business.

• Increased Competition and Market Saturation: The significant number of SPACs currently seeking acquisition targets has intensified competition, potentially driving up valuations for desirable private companies. This makes it challenging for Instinct Bio Technical Company to identify and secure a high-quality merger candidate at an attractive price within its mandated timeframe, or to find a suitable target at all.
• Adverse Investor Sentiment and Higher Redemption Rates: Following a period of high enthusiasm, investor confidence in SPACs has generally declined due to concerns about the post-merger performance of de-SPACed companies and potential shareholder dilution. This trend can lead to higher redemption rates, where shareholders choose to redeem their shares for cash before a merger is completed, leaving Instinct Bio Technical Company with less capital to finalize an acquisition and potentially necessitating more dilutive financing.
• Evolving Regulatory Landscape: Regulatory bodies, particularly the U.S. Securities and Exchange Commission (SEC), have increased their scrutiny of SPACs, proposing and implementing stricter rules regarding disclosures, accounting, and liability. These evolving regulations can increase the complexity, cost, and timeline for Instinct Bio Technical Company to complete a business combination, making the SPAC structure less appealing for potential target companies.

• Commercialization of Stem Cell Skincare and Wellness Products: As a vertically integrated company specializing in stem cell skincare and wellness products, Instinct Bio Technical Company's revenue growth will be driven by the successful development, manufacturing, distribution, and retail of its product portfolio. The company encompasses research and development, manufacturing, distribution, retail, and clinical applications in this sector.
• Strategic Expansion and Global Footprint: Instinct Bio Technical Company lists "strategic expansion" and "global footprint" as key growth pillars. This indicates that expanding into new geographical markets and strengthening its presence in existing international markets, particularly across Asia, will be a significant driver of future revenue.
• Advancements in Research and Development (R&D) and New Product Development: Continuous innovation in regenerative medicine and stem cell technology is central to the company's operations. Its focus on R&D, including proprietary stem cell technology and culture mediums, is expected to lead to new product launches and enhancements, thereby driving revenue growth.
• Scaling Manufacturing Capabilities: Increasing its manufacturing scale, which is another stated growth pillar, will enable Instinct Bio Technical Company to meet rising demand for its products, expand its market reach, and potentially improve cost efficiencies, contributing to higher revenue generation.